Syndax Pharmaceuticals (SNDX) Total Current Liabilities (2015 - 2026)

Syndax Pharmaceuticals' Total Current Liabilities history runs 12 years deep, the most recent figure standing at $86.2 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 8.86% year-over-year to $86.2 million; the TTM figure through Mar 2026 stood at $86.2 million (down 8.86% YoY), while the FY2025 annual figure was $120.1 million, up 16.0% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $86.2 million, down from $120.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $120.1 million in Q4 2025, with the low at $20.8 million in Q3 2022.
• The 5-year median for Total Current Liabilities is $50.8 million (2024), against an average of $61.6 million.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities retreated 27.55% in 2022, then soared 166.03% in 2025.
• Syndax Pharmaceuticals' Total Current Liabilities stood at $29.1 million in 2022, then jumped by 99.88% to $58.1 million in 2023, then jumped by 78.24% to $103.5 million in 2024, then advanced by 16.0% to $120.1 million in 2025, then fell by 28.26% to $86.2 million in 2026.
• Business Quant data shows SNDX's Total Current Liabilities at $86.2 million in Q1 2026, $120.1 million in Q4 2025, and $114.2 million in Q3 2025.